Who was studied?
A subset of the phase 2 obesity trial had at least 10% liver fat by MRI. This was part of that parent trial, rather than an independent new obesity cohort.
- Participants
- 98 adults
- Duration
- 24-week primary assessment; 48-week study
- Funding
- Eli Lilly
What did the study find?
At 24 weeks, average relative liver-fat reductions were 81.4% and 82.4% in the 8 mg and 12 mg groups, versus a 0.3% increase with placebo.
What should you keep in mind?
Relative liver-fat reduction is not the same as percentage points of liver fat. MRI findings do not prove reversal of fibrosis, and later imaging data were incomplete.
Why it matters
The finding suggests a metabolic question worth further study. It does not establish a cure for liver disease or a dosing recommendation.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Published 2024 · PMID 38858523 · DOI 10.1038/s41591-024-03018-2
Summary by Peptide Lit, checked against the original abstract on October 7, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.